| Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in advanced solid tumors J Strauss, CR Heery, J Schlom, RA Madan, L Cao, Z Kang, E Lamping, ... Clinical Cancer Research 24 (6), 1287-1295, 2018 | 348 | 2018 |
| Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial CR Heery, G O'Sullivan-Coyne, RA Madan, L Cordes, A Rajan, ... The Lancet Oncology 18 (5), 587-598, 2017 | 304 | 2017 |
| Phase I trial of a yeast-based therapeutic cancer vaccine (GI-6301) targeting the transcription factor brachyury CR Heery, BH Singh, M Rauckhorst, JL Marté, RN Donahue, I Grenga, ... Cancer immunology research 3 (11), 1248-1256, 2015 | 131 | 2015 |
| The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells C Jochems, M Fantini, RI Fernando, AR Kwilas, RN Donahue, LM Lepone, ... Oncotarget 7 (25), 37762, 2016 | 115 | 2016 |
| Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody RN Donahue, LM Lepone, I Grenga, C Jochems, M Fantini, RA Madan, ... Journal for immunotherapy of cancer 5, 1-16, 2017 | 91 | 2017 |
| Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab V Formica, R Palmirotta, G Del Monte, A Savonarola, G Ludovici, ... International journal of colorectal disease 26, 143-151, 2011 | 91 | 2011 |
| Docetaxel alone or in combination with a therapeutic cancer vaccine (PANVAC) in patients with metastatic breast cancer: a randomized clinical trial CR Heery, NK Ibrahim, PM Arlen, M Mohebtash, JL Murray, K Koenig, ... JAMA oncology 1 (8), 1087-1095, 2015 | 89 | 2015 |
| Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines B Farsaci, RN Donahue, MA Coplin, I Grenga, LM Lepone, AA Molinolo, ... Cancer immunology research 2 (11), 1090-1102, 2014 | 78 | 2014 |
| A fully human IgG1 anti‐PD‐L1 MAb in an in vitro assay enhances antigen‐specific T‐cell responses I Grenga, RN Donahue, LM Lepone, J Richards, J Schlom Clinical & translational immunology 5 (5), e83, 2016 | 71 | 2016 |
| Phase I study of a poxviral TRICOM-based vaccine directed against the transcription factor brachyury CR Heery, C Palena, S McMahon, RN Donahue, LM Lepone, I Grenga, ... Clinical Cancer Research 23 (22), 6833-6845, 2017 | 63 | 2017 |
| Analyses of 123 peripheral human immune cell subsets: defining differences with age and between healthy donors and cancer patients not detected in analysis of standard immune … LM Lepone, RN Donahue, I Grenga, S Metenou, J Richards, CR Heery, ... Journal of Circulating Biomarkers 5 (Godište 2016), 5-5, 2016 | 60 | 2016 |
| Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy PS Kim, C Jochems, I Grenga, RN Donahue, KY Tsang, JL Gulley, ... The Journal of Immunology 192 (6), 2622-2633, 2014 | 53 | 2014 |
| Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition … I Grenga, RN Donahue, ML Gargulak, LM Lepone, M Roselli, M Bilusic, ... Urologic Oncology: Seminars and Original Investigations 36 (3), 93. e1-93. e11, 2018 | 44 | 2018 |
| Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial CR Heery, RA Madan, MN Stein, WM Stadler, RS Di Paola, M Rauckhorst, ... Oncotarget 7 (42), 69014, 2016 | 43 | 2016 |
| Caregiver distress in the early phases of cancer R Pellegrino, V Formica, I Portarena, S Mariotti, I Grenga, G Del Monte, ... Anticancer research 30 (11), 4657-4663, 2010 | 41 | 2010 |
| Role of CA19. 9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients V Formica, MC Massara, I Portarena, V Fiaschetti, I Grenga, ... Cancer Biomarkers 5 (4-5), 167-175, 2009 | 36 | 2009 |
| Analyses of pretherapy peripheral immunoscore and response to vaccine therapy B Farsaci, RN Donahue, I Grenga, LM Lepone, PS Kim, B Dempsey, ... Cancer immunology research 4 (9), 755-765, 2016 | 32 | 2016 |
| The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy M Roselli, V Formica, V Cereda, C Jochems, J Richards, I Grenga, ... Oncoimmunology 5 (7), e1188243, 2016 | 32 | 2016 |
| Rehabilitation in neuro-oncology: a meta-analysis of published data and a mono-institutional experience V Formica, G Del Monte, I Giacchetti, I Grenga, S Giaquinto, M Fini, ... Integrative cancer therapies 10 (2), 119-126, 2011 | 30 | 2011 |
| Phase I trial of a yeast-based therapeutic cancer vaccine (GI-6301) targeting the transcription factor brachyury. Cancer Immunol Res.(2015) 3: 1248–56. doi: 10.1158/2326-6066 CR Heery, BH Singh, M Rauckhorst, JL Marte, RN Donahue, I Grenga, ... This study describes the early successes with a tumor antigen vaccine …, 0 | 30 | |
